Currently, three classes of antiestrogen treatments are available for patients with HR + BC (Table 1): selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and selective estrogen receptor degraders (SERDs) [13,16]. The gene discussed is CYP19A1; the disease is breast cancer.